A Durham, N.C.-based Duke Health-led research team advanced a regenerative osteoarthritis treatment program to its next development phase after meeting preclinical goals under the Advanced Research Projects Agency for Health’s “Novel Innovations for Tissue Regeneration in Osteoarthritis” initiative.
The effort is part of the BUD (Boston Children’s/UCLA/Duke) NextGenRegen therapeutic program, which received an initial $13M award in 2024 and could receive up to $12.5M in additional funding, according to an April 6 Duke news release.
Researchers at Duke, Los Angeles-based UCLA, Boston Children’s Hospital and Cambridge, Mass.-based Harvard University are developing three experimental treatments designed to activate the body’s natural repair processes in cartilage and underlying bone. In animal models, the drug combinations restored joint tissue to near-normal levels and reduced pain markers for long periods after treatment…